Clinical trials: ICANS
Acute Lymphoblastic Leukemia, Immune System Diseases
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03016377
- Testing
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
ICANS, Grade Unspecified, CAR T-Cell-Related Encephalopathy Syndrome
Multicenter Study Using IMC to Analyze the Impact of ICANS on Microglia
Immunotherapy with chimeric antigen receptor (CAR) T cell therapy can cause immune effector cell-associated neurotoxicity syndrome (ICANS). However, the molecular mechanisms leading to ICANS are not well understood.
- Trial name
- NCT05811117
- Testing
- There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- University of Freiburg